10 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 8 Phase 2, 3 Phase 3, 2 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 7, Terminated 1 |
| Phase 3 | 3 | Completed 2, Active not recruiting 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Neurotech Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants NT-501/revakinagene taroretcel-lwey - Macular Telangiectasia Type 2 (MacTel) | Phase 4 | Recruiting | Neurotech Pharmaceuticals | 234 | 2025-11-21 | 2026-09-25 |
| A Study to Determine the Safety and Efficacy of NT-501 With MHFM NT-501 CNTF Implant - Macular Telangiectasia Type 2 | Phase 3 | Active not recruiting | Neurotech Pharmaceuticals | 12 | 2025-03-06 | 2026-10-26 |
| Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2 NT-501 CNTF implant - Macular Telangiectasia Type 2 | Phase 2 | Completed | Neurotech Pharmaceuticals | 33 | 2021-07-21 | 2025-03-26 |
| A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol B NT-501, Sham - Macular Telangiectasia Type 2 | Phase 3 | Completed | Neurotech Pharmaceuticals | 119 | 2018-01-22 | 2024-09-24 |
| A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A NT-501, Sham Procedure - Macular Telangiectasia Type 2 (MacTel) | Phase 3 | Completed | Neurotech Pharmaceuticals | 120 | 2017-11-24 | 2024-09-24 |
| Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel) Ciliary neurotrophic factor (CNTF), Surgery - MacTel (Macular Telangiectasia) Type 2 | Phase 2 | Completed | Neurotech Pharmaceuticals | 70 | 2017-05-12 | 2025-05-09 |
| Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD) NT-503-3 ECT implantation, Eylea® injected intravitreally administered every 8 weeks - Macular Degeneration | Phase 1 / Phase 2 | Terminated | Neurotech Pharmaceuticals | 42 | 2014-09-01 | 2022-07-18 |
| A Phase 2 Multicenter Randomized Clinical Trial of CNTF for MacTel Ciliary neurotrophic factor (CNTF), Sham procedure, NT-501 Implant - Macular Telangiectasia Type 2 | Phase 2 | Completed | Neurotech Pharmaceuticals | 67 | 2014-04-01 | 2018-09-12 |
| Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa NT-501, Sham - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 | Completed | Neurotech Pharmaceuticals | 22 | 2012-01-01 | 2023-02-14 |
| Ciliary Neurotrophic Factor (CNTF) Safety Trial in Patients With Macular Telangiectasia (Mactel) NT-501 implant - Idiopathic Juxtafoveal Telangiectasia | Phase 1 | Completed | Neurotech Pharmaceuticals | 7 | 2011-05-01 | 2016-11-22 |
| A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa NT-501 - Retinitis Pigmentosa | Phase 2 | Completed | Neurotech Pharmaceuticals | 73 | 2007-01-22 | 2025-05-01 |
| A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa Low Dose NT-501, High Dose NT-501 - Retinitis Pigmentosa | Phase 2 | Completed | Neurotech Pharmaceuticals | 67 | 2007-01-08 | 2024-08-13 |
| A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration High Dose NT-501 implant, Low Dose NT-501 implant, Sham - Nonexudative Age-Related Macular Degeneration, Unspecified Eye, Intermediate Dry Stage | Phase 2 | Completed | Neurotech Pharmaceuticals | 53 | 2007-01-05 | 2025-03-28 |
Eye Diseases (3) · Retinal Diseases (3) · Retinitis Pigmentosa (3) · Idiopathic Juxtafoveal Retinal Telangiectasia (1) · Macular Degeneration (1) · Usher Syndromes (1)
Ciliary Neurotrophic Factor (5) · salicylhydroxamic acid (3) · Electroconvulsive Therapy (1) · Surgical Procedures, Operative (1)
United States (13) · Australia (7) · France (1) · Germany (1) · Israel (1) · United Kingdom (1)
Thomas Aaberg, Jr, MD (3) · Charles Johnson, MB, ChB (1) · David Birch, MD (1) · David Birch, MD, PhD (1) · Jacque Duncan, MD (1) · Mark Gillies, MD (1) · Paul S Bernstein, MD (1) · Thomas Aaberg, Jr., MD (1) · Weng Tao (1) · Weng Tao, M.D., PhD (1)
PMID 23049090, PMID 23668681, PMID 40693847, PMID 21087953, PMID 30292541, PMID 33229343